Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101246 | 1.00 | ACE (0.53) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL27231128 | 0.88 | ACE (0.64) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL19138179 | 0.83 | ITGB3 (0.58) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL16345763 | 0.83 | ITGB3 (0.58) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL19174463 | 0.83 | ITGB3 (0.60) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL27439690 | 0.82 | ITGB3 (0.61) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL27439689 | 0.82 | ITGB3 (0.61) | ACEITGB3ITGA2BPTPN1CTSS | |
| SCHEMBL4417313 | 0.81 | ITGA4 (0.62) | ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL1309887 | 0.81 | ITGA4 (0.62) | ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL838170 | 0.81 | ITGA4 (0.62) | ITGB3ITGA2BPTPN1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | ACE 2304/4885ITGB3 10/4885ITGA2B 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.